Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefadroxil
Drug ID BADD_D00379
Description Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Indications and Usage For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Marketing Status approved; vet_approved; withdrawn
ATC Code J01DB05
DrugBank ID DB01140
KEGG ID D00257; D02353
MeSH ID D002434
PubChem ID 47965
TTD Drug ID D0X9ZC
NDC Product Code 16714-390; 43063-553; 57237-096; 57237-098; 63629-7987; 63629-8253; 66267-045; 68180-180; 68788-8479; 65862-359; 16714-389; 72189-445; 80425-0198; 65862-085; 50090-6050; 63629-7988; 68180-182; 68071-5234; 16714-388; 45865-503; 63187-883; 68071-2752; 70518-2538; 50090-0580; 57237-097; 68788-7484; 68788-8261; 0093-3196; 0093-4059; 43063-595; 65862-083; 65862-084; 70518-3580; 72189-103; 50090-6356; 55289-589; 68180-181; 67296-1038; 68071-2938; 53002-2290
UNII 280111G160
Synonyms Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate
Chemical Information
Molecular Formula C16H17N3O5S
CAS Registry Number 50370-12-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute hepatic failure09.01.03.0010.001115%Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.002230%
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000558%Not Available
Anxiety19.06.02.0020.000558%
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Blood bilirubin increased13.03.04.018--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.0190.000558%Not Available
Cholestasis09.01.01.001--Not Available
Complications of transplanted liver12.02.09.014; 09.01.08.011--Not Available
Condition aggravated08.01.03.0040.000558%Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.0020.000558%
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.001896%Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.0040.000558%
Eosinophilia01.02.04.001--
Erythema23.03.06.0010.000558%Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages